Biosecurity · Glycan Engineering

Biodefense Initiatives

Prevent infection. Protect vital organs. Secure essential medicines.

Programmable Glycan Design and Synthesis

Glycan Engineering| CellFlow

Structurally defined glycans with enzymatic precision at synthetic speed.

Biodefense

Our Initiatives

Viral Prevention

Inhaled Antiviral siRNA

Cell-selective protection at the site of infection.

1The Problem

Respiratory viruses enter through the airway epithelium.

Protecting these cells could help prevent infection and limit its spread, with an approach designed to work across viral strains.

2The Approach

Deliver siRNA directly to the epithelial cells viruses infect.

siRNA·Targets host pathways involved in viral infection and cellular defense.

Inhaled·Delivers treatment directly to the respiratory tract.

Cell-selective·Uses glycan ligands to target epithelial cells while limiting exposure elsewhere.

Inhaled siRNA designed to target respiratory epithelial cells and modulate host pathways to help prevent viral infection.

BIOX-2

Tissue Repair & Regeneration

Heparin-Mimetic for prevention of acute organ/tissue damage

1The Problem

Acute organ damage destroys the endothelial and epithelial barriers that protect every organ.

Once compromised, fluid leaks, inflammation cascades, and tissue dies. From ARDS to sepsis to radiation injury — there are no approved therapies that directly restore these barriers.

2The Molecule

A non-anticoagulant heparan sulfate mimetic engineered to restore barrier function across organs.

Stabilizes growth factors (FGF, VEGF)—accelerates repair

Preserves glycocalyx barrier—protects epithelium and endothelium

Neutralizes DAMPs & histones—dampens inflammation

Inhibits heparanase—prevents ECM breakdown & fibrosis

Acute Respiratory Distress Syndrome
Lead Indication

Acute Respiratory Distress Syndrome

ARDS destroys the alveolar-capillary barrier, causing fluid to flood the lungs. BIOX-2 stabilizes the endothelial glycocalyx to restore barrier integrity and protect lung tissue.

VOD/SOS Prophylaxis
Lead Indication

VOD/SOS Prophylaxis

Veno-occlusive disease damages the hepatic sinusoidal lining after bone marrow conditioning. BIOX-2 protects the liver endothelium during transplant conditioning to prevent barrier breakdown.

Sepsis & Systemic Inflammation
Expansion

Sepsis & Systemic Inflammation

Sepsis degrades the glycocalyx systemically, causing vascular leak and cytokine-driven injury across organs. BIOX-2 neutralizes histones and DAMPs to dampen the inflammatory cascade.

Radiation-Induced GI Damage
Expansion

Radiation-Induced GI Damage

GI mucositis after radiation or nuclear exposure destroys the gut lining. BIOX-2 preserves epithelial tight junctions and accelerates mucosal repair of the intestinal barrier.

BIOX-1

Anticoagulant — Securing heparin's supply

The world's most prescribed anticoagulant depends on a concentrated, overseas supply chain.
We're building domestic production of heparin — a world-essential medicine.

12M+

patients treated annually

in the U.S.

80%

API production in China

single-source dependency

100+

deaths from contaminated heparin

2008 crisis →
1B+

pigs required per year

global supply chain

An essential medicine,

Our chemoenzymatic process enables production of heparin medicines structurally and functionally equivalent to both unfractionated heparin and enoxaparin (Lovenox®).

Domestic production, reducing reliance on offshore supply
Distributed & population-scale manufacturing
Potency validated (Anti-Xa, Anti-IIa)
Tunable composition — a path to next-generation heparins
Historical Precedent

The Insulin Story

% Insulin Volume Split by Type

0%25%50%75%100%198219861990199419982002200620102014
Animal InsulinRecombinant InsulinRecombinant Insulin Analogue

Source: RethinkX, IMS Health, Washington Post, Novo Nordisk

Discovery & First Use

Insulin was discovered in the 1920s and produced from cattle pancreases for decades.

Recombinant Production

In 1982, the FDA approved Genentech’s synthetic human insulin — made from recombinant DNA, not animal tissue.

The Parallel

Recombinant insulin secured supply first — then made better insulins possible. Chemoenzymatic heparin can follow the same path.

Deployment

Our Focus in Essential Medicines

Acute Care

Acute Care

Hospital & critical care

  • Anticoagulation for surgery, dialysis and interventional procedures
  • Barrier protection in ARDS, sepsis and transplant conditioning
Outpatient

Outpatient

Community & chronic care

  • LMWH for post-discharge and extended prophylaxis
  • Home- and self-administered dosing
Preparedness

Preparedness

Strategic stockpile & field deployment

  • Inhaled broad spectrum antiviral prophylaxis
  • Mass-casualty injury response
Manufacturing

CellFlow Scale-Up

Manufacturing facility

CellFlow Synthesis

U.S. Expansion with Partners

Distributed, scalable manufacturing — from factory floor to forward deployment.

  • High-purity, modular scale-up
  • Unprecedented biomolecule design space
  • Precise control of branching, sulfation, and epimerization

Other Approaches

Chemical Synthesis

Limited design space, harsh reagents, expensive

Animal Extraction

Inconsistent structures, supply risk

Recombinant Production

Imprecise glycan control, low yields

Bioreactor system
Get In Touch

Connect with us